Table 3 Association between the breast cancer cell subsets and patients’ clinical features
Clinical parameters | CD24 +  | P value | CD44 +  | P value | CD44 + CD24- | P value | CD44 + CK + /EPCAM +  | P value | |
|---|---|---|---|---|---|---|---|---|---|
Grade | 2 | 13.8 (0.1–37) | 0.353 | 28 (3.6–66) | 0.906 | 30 (0.1–68) | 0.502 | 40 (6–88.7) | 0.937 |
3 | 11.7 (0.9–34) | 22 (1.3–75) | 34 (4.7–80) | 41 (0.5–93) | |||||
Tumor type | IDC | 12.3 (0.9–37) | 0.342 | 23.7 (1.3–75) | 0.166 | 26 (2–80) | 0.076 | 53 (0.5–93) | 0.390 |
ILC | 12.6 (0.9–347) | 59 (16–63) | 63.5 (44.6–71) | 40 (13–42) | |||||
LN | − ve | 11.5 (0.1–34) | 0.273 | 21 (1–63) | 0.507 | 22.5 (0.1–71) | 0.654 | 65 (5.7–93) | 0.219 |
 + ve | 12.5 (0.9–37) | 26 (3.6–75) | 33.5 (2–80) | 36 (0.5–93) | |||||
Metastasis | − ve | 12 (0.1–37) | 0.355 | 21 (1.3–66) | 0.071 | 25.3 (0.1–68) | 0.038 | 40 (0.5–93) | 0.821 |
 + ve | 18 (4–34) | 53.8 (6.5–75) | 61 (7–80) | 48 (3.5–79) | |||||
ER | − ve | 12 (0.1–34) | 0.953 | 16.5 (1.3–66) | 0.059 | 22.5 (0.1–71) | 0.23 | 56 (3.5–93) | 0.336 |
 + ve | 12 (0.9–37) | 38.6 (3.6–75) | 48 (2–79.7) | 37.7 (0.5–87) | |||||
PR | − ve | 12 (0.1–34) | 0.953 | 16.5 (1.3–66) | 0.059 | 22.5 (0.1–71) | 0.23 | 56 (3.5–93) | 0.336 |
 + ve | 12 (0.9–37) | 38.6 (3.6–75) | 48 (2–79.7) | 37.7 (0.5–87) | |||||
HER2 | − ve | 12 (0.1–37) | 1.00 | 28 (1.3–74.7) | 0.473 | 33.5 (0.1–80) | 0.695 | 41 (3.5–93) | 0.872 |
 + ve | 12.5 (0.9–34) | 23.7 (3.6–58) | 30 (4–64.8) | 40 (0.5–87) | |||||
Capsular invasion | − ve | 11.6 (0.1–43) | 0.708 | 23.8 (1.3–66) | 0.953 | 37 (0.1–71) | 0.798 | 40 (5.7–93) | 0.828 |
 + ve | 12.3 (0.9–37) | 26 (3.6–74.7) | 28 (2–79.7) | 49 (0.5–93) | |||||